BioCentury | Oct 11, 1999
Company News

VivoRx, Mylan Laboratories Inc. gene/cell therapy, metabolic news

...1). Under the settlement, Mylan accepted title to an office building owned by VivoRx, and VivoRx...
...back the facility for four years from Mylan with an option to repurchase the building. VivoRx...
...Mylan in May to cover a portion of Mylan's R&D funding provided under the agreement. VivoRx Inc....
BioCentury | Jun 1, 1999
Company News

VivoRx, Mylan Laboratories Inc. gene/cell therapy, metabolic news

...under the companies’ 1994 agreement to develop VivoRx’s encapsulated cell therapies to treat diabetes. However, VivoRx...
...Under the decision, Mylan’s exclusive North American rights to VivoRx’s diabetes technologies have been terminated. VivoRx...
...value of the VivoRx facility, VivoRx has resources to operate for up to three years. VivoRx Inc....
BioCentury | Mar 29, 1999
Company News

VivoRx, Mylan Laboratories Inc. gene/cell therapy, metabolic news

...Court against VivoRx, the company's directors and officers and other companies owned or controlled by VivoRx's...
...officers and directors for alleged improprieties regarding the funding. Mylan had been funding development of VivoRx's...
...since 1994. Mylan was scheduled to provide $2.5 million per quarter in research funding to VivoRx...
BioCentury | Feb 22, 1999
Tools & Techniques

Cell therapy inching ahead

...cells to treat metastatic breast cancer patients undergoing stem cell transplantation. In the metabolic area, VivoRx Inc....
...cells to treat metastatic breast cancer patients undergoing stem cell transplantation. In the metabolic area, VivoRx Inc....
BioCentury | Dec 14, 1998
Tools & Techniques

Diabetes Pipeline

...Regulate glucose metabolism Phase II TheraTech (THRT) GLP-1 glucagon-like peptide-1 Regulate glucose metabolism Phase II VivoRx...
BioCentury | Apr 27, 1998
Emerging Company Profile

Islet: Finding safety in seaweed

...the encapsulation process made since February 1994. The company will pay royalties to the university. VivoRx Inc....
...has experimented with alginate-polylysine mixtures and polyethylene glycol to encapsulate islets in its BetaRx system. VivoRx...
BioCentury | Sep 22, 1997
Tools & Techniques

Template for renewable know-how

...develop a cell therapeutic delivery system at VivoRx Inc. (Santa Monica, Calif.). That deal also gave VivoRx...
BioCentury | Jul 14, 1997
Company News

American Pharmaceutical Partners, Glaxo Wellcome Inc. deal

...500 and 1000 mg formulations of lyophilized acyclovir to American Pharmaceutical Partners, a subsidiary of VivoRx...
BioCentury | Jan 13, 1997
Company News

HemoCleanse Inc., Monsanto deal

...collaborating on the testing and development of the device. HemoCleanse also has an agreement with VivoRx...
BioCentury | Sep 30, 1996
Politics, Policy & Law

Next move on xenotransplants; Biotech lobbying $$$

...liver failure,. - University of California, San Francisco: Baboon bone marrow transplant for HIV. - VivoRx...
Items per page:
1 - 10 of 18
BioCentury | Oct 11, 1999
Company News

VivoRx, Mylan Laboratories Inc. gene/cell therapy, metabolic news

...1). Under the settlement, Mylan accepted title to an office building owned by VivoRx, and VivoRx...
...back the facility for four years from Mylan with an option to repurchase the building. VivoRx...
...Mylan in May to cover a portion of Mylan's R&D funding provided under the agreement. VivoRx Inc....
BioCentury | Jun 1, 1999
Company News

VivoRx, Mylan Laboratories Inc. gene/cell therapy, metabolic news

...under the companies’ 1994 agreement to develop VivoRx’s encapsulated cell therapies to treat diabetes. However, VivoRx...
...Under the decision, Mylan’s exclusive North American rights to VivoRx’s diabetes technologies have been terminated. VivoRx...
...value of the VivoRx facility, VivoRx has resources to operate for up to three years. VivoRx Inc....
BioCentury | Mar 29, 1999
Company News

VivoRx, Mylan Laboratories Inc. gene/cell therapy, metabolic news

...Court against VivoRx, the company's directors and officers and other companies owned or controlled by VivoRx's...
...officers and directors for alleged improprieties regarding the funding. Mylan had been funding development of VivoRx's...
...since 1994. Mylan was scheduled to provide $2.5 million per quarter in research funding to VivoRx...
BioCentury | Feb 22, 1999
Tools & Techniques

Cell therapy inching ahead

...cells to treat metastatic breast cancer patients undergoing stem cell transplantation. In the metabolic area, VivoRx Inc....
...cells to treat metastatic breast cancer patients undergoing stem cell transplantation. In the metabolic area, VivoRx Inc....
BioCentury | Dec 14, 1998
Tools & Techniques

Diabetes Pipeline

...Regulate glucose metabolism Phase II TheraTech (THRT) GLP-1 glucagon-like peptide-1 Regulate glucose metabolism Phase II VivoRx...
BioCentury | Apr 27, 1998
Emerging Company Profile

Islet: Finding safety in seaweed

...the encapsulation process made since February 1994. The company will pay royalties to the university. VivoRx Inc....
...has experimented with alginate-polylysine mixtures and polyethylene glycol to encapsulate islets in its BetaRx system. VivoRx...
BioCentury | Sep 22, 1997
Tools & Techniques

Template for renewable know-how

...develop a cell therapeutic delivery system at VivoRx Inc. (Santa Monica, Calif.). That deal also gave VivoRx...
BioCentury | Jul 14, 1997
Company News

American Pharmaceutical Partners, Glaxo Wellcome Inc. deal

...500 and 1000 mg formulations of lyophilized acyclovir to American Pharmaceutical Partners, a subsidiary of VivoRx...
BioCentury | Jan 13, 1997
Company News

HemoCleanse Inc., Monsanto deal

...collaborating on the testing and development of the device. HemoCleanse also has an agreement with VivoRx...
BioCentury | Sep 30, 1996
Politics, Policy & Law

Next move on xenotransplants; Biotech lobbying $$$

...liver failure,. - University of California, San Francisco: Baboon bone marrow transplant for HIV. - VivoRx...
Items per page:
1 - 10 of 18